Data demonstrate engineered tRNA from company's first development candidate restores protein production to clinically meaningful levels in two disease models driven by the same premature termination ...

Alltrna is advancing a new class of genetic medicines based on the power of tRNA biology to universally treat Stop Codon Disease, which encompasses thousands of genetic diseases caused by a premature ...

(A) Suppressor tRNA readthrough strategy. Natural tRNAs with engineered anticodons are charged with canonical amino acids to enable readthrough of the premature termination codon (PTC). (B) Unnatural ...

Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, No. 10 (March 10, 2015), pp. 3038-3043 (6 pages) Premature termination codons (PTCs) in an mRNA ORF ...

Alltrna Inc. raised $109 million in a series B round to back its work with transfer RNA, with the first targeted indication of stop codon disease: a condition that takes in thousands of rare and ...

This is a preview. Log in through your library . PNAS is the world's most-cited multidisciplinary scientific serial. It publishes high-impact research reports, commentaries, perspectives, reviews, ...

A team of researchers at the Broad Institute, led by gene-editing pioneer David Liu, has developed a new genome-editing strategy that could potentially lead to a one-time treatment for multiple ...